[1-PHENYL-3-(PYRIDIN-3-YL)-1H-PYRAZOL-4-YL]-[4-(4-TRIFLUOROMETHYL-PHENYL)-PIPERAZIN-1-YL]METHANONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ACJJWAAHVYYMEV-UHFFFAOYSA-N
Smiles	FC(F)(F)c1ccc(cc1)N2CCN(CC2)C(=O)c3cn(nc3c4cccnc4)c5ccccc5
InChI	InChI=1S/C26H22F3N5O/c27-26(28,29)20-8-10-21(11-9-20)32-13-15-33(16-14-32)25(35)23-18-34(22-6-2-1-3-7-22)31-24(23)19-5-4-12-30-17-19/h1-12,17-18H,13-16H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H22F3N5O
Molecular Weight	477.48
AlogP	4.84
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	5.0
Polar Surface Area	54.26
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	35.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by MTT assay	Homo sapiens	16910.0 nM
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	Homo sapiens	75340.0 nM
Cytotoxicity against Homo sapiens (human) Raji cells after 48 hr by MTT assay	Homo sapiens	15120.0 nM
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay	Homo sapiens	100000.0 nM
Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	Homo sapiens	28550.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2295852
PubChem	76324064

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).